FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966106742> ?p ?o ?g. }

• W1966106742 endingPage "192" @default.
• W1966106742 startingPage "186" @default.
• W1966106742 abstract "Patients with recurrent or metastatic HNC have a poor response and survival with currently available chemotherapy agents. Thus, new agents are needed. The authors report the results of a phase II trial of irinotecan and cisplatin in patients with metastatic or recurrent HNC.Patients were treated with irinotecan 65 mg/m2 IV over 90 minutes and cisplatin 30 mg/m2 were administered intravenously weekly for four weeks, followed by a two week rest. However, after 17 patients were treated with weekly irinotecan at a dose of 65 mg/m2, toxicity analysis demonstrated the poor tolerance of that dose in this patient population. Thus, the protocol was amended, and irinotecan was dose reduced to a starting dose of 50 mg/m2. Twenty-three additional patients were treated with this dose.Forty patients were enrolled on study between February 2002 and April 2006, 17 patients at the first dose level and 23 patients at the amended dose level. Overall, 12 of 17 patients (71%) treated with irinotecan 65 mg/m2 experienced clinically significant grade 3 or 4 toxicity. Twelve patients required dose reductions. Toxicity was reduced but 17% of patients still experienced grade 3 or 4 toxicity on the lower irinotecan dose. The response rate was 35% for patients treated at irinotecan 65 mg/m2 and 22% for patients treated at 50 mg/m2. No complete responses were noted.The combination of irinotecan and cisplatin is efficacious in a poor prognosis group of patients but toxicity is substantial." @default.
• W1966106742 created "2016-06-24" @default.
• W1966106742 creator A5011202941 @default.
• W1966106742 creator A5012722706 @default.
• W1966106742 creator A5016127308 @default.
• W1966106742 creator A5017367541 @default.
• W1966106742 creator A5024446648 @default.
• W1966106742 creator A5026253647 @default.
• W1966106742 creator A5045462759 @default.
• W1966106742 creator A5048060803 @default.
• W1966106742 creator A5055632876 @default.
• W1966106742 creator A5091586329 @default.
• W1966106742 date "2008-07-01" @default.
• W1966106742 modified "2023-09-27" @default.
• W1966106742 title "Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck" @default.
• W1966106742 cites W1952422131 @default.
• W1966106742 cites W1971928740 @default.
• W1966106742 cites W1992918749 @default.
• W1966106742 cites W2009608310 @default.
• W1966106742 cites W2016386446 @default.
• W1966106742 cites W2018029718 @default.
• W1966106742 cites W2029409133 @default.
• W1966106742 cites W2044210486 @default.
• W1966106742 cites W2045786482 @default.
• W1966106742 cites W2095822339 @default.
• W1966106742 cites W2101423153 @default.
• W1966106742 cites W2109261874 @default.
• W1966106742 cites W2142564546 @default.
• W1966106742 cites W2144233828 @default.
• W1966106742 cites W2146387437 @default.
• W1966106742 cites W2152853935 @default.
• W1966106742 cites W2170596177 @default.
• W1966106742 cites W2174727426 @default.
• W1966106742 cites W4247164694 @default.
• W1966106742 cites W4247915047 @default.
• W1966106742 cites W1991355508 @default.
• W1966106742 doi "https://doi.org/10.1002/cncr.23545" @default.
• W1966106742 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18484593" @default.
• W1966106742 hasPublicationYear "2008" @default.
• W1966106742 type Work @default.
• W1966106742 sameAs 1966106742 @default.
• W1966106742 citedByCount "12" @default.
• W1966106742 countsByYear W19661067422012 @default.
• W1966106742 countsByYear W19661067422014 @default.
• W1966106742 countsByYear W19661067422015 @default.
• W1966106742 countsByYear W19661067422016 @default.
• W1966106742 countsByYear W19661067422018 @default.
• W1966106742 countsByYear W19661067422021 @default.
• W1966106742 countsByYear W19661067422022 @default.
• W1966106742 crossrefType "journal-article" @default.
• W1966106742 hasAuthorship W1966106742A5011202941 @default.
• W1966106742 hasAuthorship W1966106742A5012722706 @default.
• W1966106742 hasAuthorship W1966106742A5016127308 @default.
• W1966106742 hasAuthorship W1966106742A5017367541 @default.
• W1966106742 hasAuthorship W1966106742A5024446648 @default.
• W1966106742 hasAuthorship W1966106742A5026253647 @default.
• W1966106742 hasAuthorship W1966106742A5045462759 @default.
• W1966106742 hasAuthorship W1966106742A5048060803 @default.
• W1966106742 hasAuthorship W1966106742A5055632876 @default.
• W1966106742 hasAuthorship W1966106742A5091586329 @default.
• W1966106742 hasConcept C121608353 @default.
• W1966106742 hasConcept C126322002 @default.
• W1966106742 hasConcept C126894567 @default.
• W1966106742 hasConcept C141071460 @default.
• W1966106742 hasConcept C2776694085 @default.
• W1966106742 hasConcept C2778239845 @default.
• W1966106742 hasConcept C2780259306 @default.
• W1966106742 hasConcept C2908647359 @default.
• W1966106742 hasConcept C29730261 @default.
• W1966106742 hasConcept C526805850 @default.
• W1966106742 hasConcept C71924100 @default.
• W1966106742 hasConcept C90924648 @default.
• W1966106742 hasConcept C99454951 @default.
• W1966106742 hasConceptScore W1966106742C121608353 @default.
• W1966106742 hasConceptScore W1966106742C126322002 @default.
• W1966106742 hasConceptScore W1966106742C126894567 @default.
• W1966106742 hasConceptScore W1966106742C141071460 @default.
• W1966106742 hasConceptScore W1966106742C2776694085 @default.
• W1966106742 hasConceptScore W1966106742C2778239845 @default.
• W1966106742 hasConceptScore W1966106742C2780259306 @default.
• W1966106742 hasConceptScore W1966106742C2908647359 @default.
• W1966106742 hasConceptScore W1966106742C29730261 @default.
• W1966106742 hasConceptScore W1966106742C526805850 @default.
• W1966106742 hasConceptScore W1966106742C71924100 @default.
• W1966106742 hasConceptScore W1966106742C90924648 @default.
• W1966106742 hasConceptScore W1966106742C99454951 @default.
• W1966106742 hasIssue "1" @default.
• W1966106742 hasLocation W19661067421 @default.
• W1966106742 hasLocation W19661067422 @default.
• W1966106742 hasOpenAccess W1966106742 @default.
• W1966106742 hasPrimaryLocation W19661067421 @default.
• W1966106742 hasRelatedWork W2036555741 @default.
• W1966106742 hasRelatedWork W2049010176 @default.
• W1966106742 hasRelatedWork W2090850966 @default.
• W1966106742 hasRelatedWork W2235203422 @default.
• W1966106742 hasRelatedWork W2353647715 @default.
• W1966106742 hasRelatedWork W2355288882 @default.
• W1966106742 hasRelatedWork W2368228325 @default.

• next